RTKs can activate Ras, a protein that is tethered to the plasma membrane, by causing it to bind GTP. Once activated, Ras can do a variety of things. In this example, it activates an enzymatic ...

Cotargeting other parallel pathways would be justified if they are ... the nearly 3.4 million patients who receive a diagnosis of RAS-mutant cancer each year.

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

"Our findings represent a breakthrough in the treatment of HCM in children, particularly those suffering from severe forms of the disease due to genetic variants in the RAS/MAPK pathway," said ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...